5

10

ABSTRACT OF THE DISCLOSURE

The present invention relates to Ca²⁺ channel blockers and more particularly to the R-type Ca²⁺ channel blockers. More specifically, the invention relates to Ca²⁺ channel blockers activity of *Mandevilla velutina* and *Mandevilla illustris*. The present invention further concerns saponin-like compounds isolated from *Mandevilla* species. The present invention also relates to the treatment of several pathologies that involve the nifedipine-insensitive but isradipine sensitive steady-state R-type Ca²⁺ channel and the use of steady-state R-type Ca²⁺ channel blockers in the treatment of these pathologies.